



The TIMI Trials

InTIME II-TIMI 17

OBJECTIVE: To compare the single-bolus fibrinolytic agent lanoteplase (nPA) with accelerated rtPA for the treatment of patients with ST elevation myocardial infarction.

1. **The InTIME-II Investigators. Intravenous nPA for the treatment of infarcting myocardial early: InTIME-II, a double blind comparison of single bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J. 2000; 21: 2005-2013.**
2. Giugliano RP, Llevadot J, Antman EM, McCabe CH, Foxley A, Skene A, Wilcox R, Chew P, Neuhaus K-L, Braunwald E. Geographic variation among hospitals participating in a world-wide thrombolytic trial: An InTIME-II substudy. *Eur Heart J* 1999;20:519.
3. Llevadot J, Giugliano RP, Antman EM, McCabe CH, Foxley A, Skene A, Wilcox R, Chew P, Neuhaus K-L, Braunwald E. Hospital profiles and clinical outcomes stratified by on-site catheterization availability. An InTIME-II substudy. *Eur Heart J* 1999;20:356.
4. de Lemos JA, Antman EM, Giugliano RP, Morrow DA, McCabe CH, Charlesworth A, Schroeder R, Braunwald E, for the InTIME II Investigators. Very early risk stratification after thrombolytic therapy using a bedside myoglobin assay and the 12-lead ECG. *Am Heart J* 2000; 140: 373-8.
5. de Lemos JA, Antman EM, Giugliano RP, Morrow DA, McCabe CH, Cutler SS, Charlesworth A, Schroeder R, Braunwald E for the InTIME-II Investigators. Comparison of a 60-minute vs. 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. *Am J Cardiol* 2000; 86: 1235 -7.
6. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy S, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous NPA for treatment of infarcting myocardium InTIME II trial substudy. *Circulation* 2000; 102:2031-2037.
7. de Lemos JA, Schroeder R, Antman EM, McCabe CH, Charlesworth A, Giugliano RP, Neuhaus KL, Braunwald E. Comparison of 60 vs. 90 minute measurement of ST-segment resolution after thrombolytic therapy. *J Am Coll Cardiol* 2000; 35 (Suppl A): 397.
8. Morrow DA, Guigliano RP, Charlesworth A, Cairns R, Cutler SS, de Lemos JA, McCabe CH, Braunwald E. Revascularization practice patterns: a risk-adjusted analysis using the TIMI risk score for STEMI in InTIME-II. *Circulation* 2000; 102(Suppl II): II-846.
9. Piana RN, Giugliano RP, Coulter SA, deLemos JA, McCabe JA, Antman EM, Skene AM, Neuhaus KL, Braunwald E. Clinical outcome remains poor in diabetics with myocardial infarction despite early fibrinolytic therapy: findings from InTIME-II. *J Am Coll Cardiol* 2000; 35 (Suppl A): 407A-8A.
10. Warnica W, Antman EM, Wilcox R, McCabe C, Neuhaus K, Braunwald E. Recurrent ischemia and clinical outcome after thrombolysis for myocardial infarction: observations from InTIME-II. *J Am Coll Cardiol* 2000; 35(Suppl A): 386A.
11. Giugliano RP, Antman EM, Thompson SL, McCabe CH, Braunwald E. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality. *J Am Coll Cardiol* 2001;37(Suppl):316A.
12. Giugliano RP, Levadot J, Wilcox RD, Gurfinkel EP, McCabe CH, Charlesworth A, Thompson SL, Antman EM, Braunwald E, for the InTIME-II Investigators. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis: results from InTIME-II. *Eur Heart J* 2001; 22: 1702-15.
13. Giugliano RP, McCabe CH, Antman EM, Cannon CP, Van de Werf F, Wilcox RG, Braunwald E, for the Thrombolysis in Myocardial Infarction (TIMI) Investigators. Lower dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. *Am Heart J* 2001; 141: 742-50.

14. Llevadot J, Giugliano RP, Antman EM, Wilcox RG, Gurfinkel EP, Henry T, McCabe CH, Charlesworth A, Thompson S, Nicolau JC, Tebbe U, Sadowski Z, Braunwald E. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. *Eur Heart J* 2001;22:2104-15.
15. Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, de Lemos JA, McCabe CH, Braunwald E. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. *Lancet* 2001;358:1571-5.
16. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. *JAMA* 2001;286:1356-9.
17. Sloan MA, Giugliano RP, Thompson SL, Antman EM, McCabe CH, Braunwald E. Prediction of intracranial hemorrhage in the InTIME-II trial. *J Am Coll Cardiol* 2001; 37 (Suppl A): 372A.
18. Antman EM, Cooper HA, Gibson CM, de Lemos JA, McCabe CH, Giugliano RP, Coussement P, Murphy S, Scherer J, Anderson K, Van de Werf F, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction: Insights from TIMI 14 and InTIME-II. *Eur Heart J* 2002;23:928-933.
19. Christenson RH, Leino EV, Giugliano RP, Bahr RD. Usefulness of Prodromal Unstable Angina Pectoris in Predicting Better Survival and Smaller Infarct Size in Acute Myocardial Infarction (The InTIME-II Prodromal Symptoms Substudy). *Am J Cardiol* 2003;92:598-600.